SCHEMBL26464699

SCHEMBL26464699

CCCC(CC)c1ccc(C(F)(F)F)cc1OC

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 4/20 0.43
CRHR1 P34998 3/20 0.40
PPARD Q03181 5/20 0.37
PPARA Q07869 5/20 0.37
PPARG P37231 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
HTR2A P28223 1/20 0.36
RAB9A P51151 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26466884 0.80 PDE2A (0.62) PDE2APPARDPPARAPPARG
SCHEMBL18647920 0.80 KDM4E (0.40) HTR2AKCNH2
SCHEMBL21725448 0.79 PDE2A (0.55) PDE2ALMNACYP1A2CYP2C9CYP2C19
SCHEMBL22544367 0.77 PDE2A (0.50) PDE2ALMNACYP1A2KCNH2
SCHEMBL22871117 0.77 PDE2A (0.43) PDE2AL3MBTL1LMNAMAPTATM
SCHEMBL13698776 0.76 PDE2A (0.46) PDE2AL3MBTL1MAPTHTR2ARAB9A
SCHEMBL21725664 0.75 PDE2A (0.42) PDE2A
SCHEMBL19003505 0.74 POLB (0.47) L3MBTL1
SCHEMBL21725505 0.73 CRHR1 (0.40) CRHR1PPARGAKR1C3AKR1C2
SCHEMBL17763832 0.73 PDE2A (0.44) PDE2AL3MBTL1MAPTHTR2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135560-A1 GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF MC1R, MC3R, MC2R PDE2A 1028/4885CRHR1 46/4885PPARD 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.